FOI - Adverse events with Solensia
Published 13 January 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/vmd-foieir-requests-october-2025/foi-adverse-events-with-solensia
ATI1124 Request
Request for previous reports of bilateral hindlimb weakness/paresis and ataxia adverse reactions with Solensia.
Our reply
Solensia is a veterinary medicinal product (VMP) used for alleviation of pain associated with osteoarthritis in cats.
Zoetis has reported this case to VMD. The case reference is GBR-ZOETISPV-2025-UK-04417.
Please be aware the data are not subject to independent verification and the VMD does not guarantee their accuracy. The figures are based on adverse events submitted to the VMD for the purposes of pharmacovigilance.
We have included all adverse event reports. This includes reports where more than one product was used, reports when the product was used off-label, that is using a medicine in a way that is not specified on the product’s label, or reports where, on further evaluation, there may have been other reasons for the adverse event occurring.
Evaluation is dependent on the accuracy and quality of data received from veterinary professionals and animal owners, and reporting frequency can vary over time (reporting frequency may be affected by a product being new to the market or social media interest, for example).
All adverse events submitted to the VMD have their clinical signs coded using the Veterinary Dictionary for Drug Regulatory Activities (VeDDRA). We have provided you with the number of adverse event reports for Solensia for limb weakness, hind limb paresis and hind limb ataxia by low level term (LLT), which is one of the hierarchical levels of VeDDRA. Further information regarding VeDDRA can be located on the European Medicines Agency website, including the VeDDRA list of clinical terms for reporting suspected adverse events and the Guidance notes on the use of VeDDRA terminology.
You requested “to find out if this reaction has been seen in other cases and how many times.”
In our database that holds data from cases occurring in the United Kingdom, there are 26 cases that include the LLT limb weakness, 14 cases that include the LLT hind limb paresis and 19 cases associated with the LLT hind limb ataxia following the use of Solensia. These figures include the case you have reported.
Although adverse event report information can be useful to provide a general overview of a VMP, it is important for any clinical decisions regarding the use of a VMP to be based on a risk-benefit discussion specific to the animal or group of animals being administered the VMP. An overall frequency of an adverse event occurring for a VMP does not reflect the actual risk for an individual animal, as there are many individual factors that may contribute to the likelihood of an adverse event occurring.
All medicines whether for human or animal use come with risk, and the benefits of use in wider populations need to outweigh the potential risks. Information on adverse events that have been known to occur following administration of a particular product are summarised in sections 3.6/4.6 of the Summary of Product Characteristics (SPC). The SPC is a document describing the properties and the officially approved conditions of use of a medicine. The SPC and associated product information are updated as new information is available, and the latest version of an SPC can be found on our publicly available Product Information Database. We continually assess and update our findings relating to products used within the United Kingdom and should there be sufficient data to suggest that an SPC requires alteration or that another appropriate action is required, this will be carried out within the required timeframe, as set out by the current legislation surrounding that veterinary medicinal product or region.
Pharmacovigilance updates are published on gov.uk at https://www.gov.uk/guidance/urgent-safety-updates-for-veterinary-medicines; this also includes any updates involving non-veterinary medicines used in animals. To receive these pharmacovigilance updates via email, please click on the ‘Get emails about this page’ button. The latest update on Solensia can be found at Solensia 7 mg/ml Solution for Injection for Cats - GOV.UK (https://www.gov.uk/government/news/solensia-7-mgml-solution-for-injection-for-cats).